<DOC>
	<DOCNO>NCT00796107</DOCNO>
	<brief_summary>This study determine safety efficacy R1507 combination letrozole patient advance breast cancer . In first part study cohort patient advance breast cancer receive letrozole 2.5mg po daily combination R1507 16mg/kg every 3 week . A second cohort patient either progressed plateaued letrozole treatment receive 3-weekly cycle combination treatment letrozole R1507 . The anticipated time study treatment disease progression unacceptable toxicity , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study R1507 Combination With Letrozole Postmenopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>postmenopausal female patient ; stage IV locally advance breast cancer ; measurable disease ; letrozole failure ( Part 2 ) ; Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 . previous chemotherapy metastatic breast cancer ; concurrent antibody immunotherapy advance disease , within 4 week prior receipt study drug ; history primary malignancy 5 year prior study , exclude adequately treat basal squamous cell cancer skin , cancer situ cervix ; concurrent radiotherapy , radiotherapy within 28 day prior receipt study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>